Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Bio-Techne Corporation (TECH) 53rd Annual Nasdaq Investor Conference December 9, 2025 4:30 AM ESTCompany ParticipantsKim Kelderman - CEO, President ...

The global market is estimated at USD 25,900.5 million in 2025 and is forecast to reach USD 64,187.5 million by 2035, ...

dA new article published in the Journal of Dental Research explores the development of an integrated data-cleaning and ...

Utilities that provide natural gas to customers are investing in smart technologies to modernize their infrastructure. These ...

Federal regulators reshape path for one of the Gulf Coast’s largest LNG projects—with the decision influencing how construction unfolds.

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

Expanding applications of genomics, proteomics, transcriptomics, and metabolomics accelerate clinical development, with North America leading and Asia Pacific emerging as the fastest-growing ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...